AttendMe Owl Logo
AttendMe
Evidence Evolution
Infectious DiseaseInfectious Disease

How This Evidence Evolved

MDR Gram-Negative Treatment

New Weapons Against Resistant Pathogens

11.3

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The spread of resistant Gram-negative pathogens has driven evaluation of alternatives to polymyxins. The MCR-1 study identified a transferable plasmid-mediated colistin resistance mechanism in China; MCR-1 production negated colistin efficacy in an animal model. In the prospective CRACKLE cohort of CRE infections at mixed sites, adjusted 30-day hospital mortality was 9% with initial ceftazidime–avibactam versus 32% with initial colistin. These observational findings supported further testing of targeted agents rather than assuming colistin remained the only option.
Proof

Landmark RCTs and pivotal trials that established the evidence base

CRACKLE prospectively compared patients initially treated with ceftazidime–avibactam or colistin for CRE infections. Adjusted 30-day hospital mortality was 9% versus 32%; most patients received additional anti-CRE drugs, and randomized confirmation was needed. TANGO II studied meropenem–vaborbactam, not ceftazidime–avibactam. Among 47 patients with confirmed CRE, clinical cure at treatment end was 65.6% versus 33.3% with best available therapy (P=0.03). Day-28 mortality was 15.6% versus 33.3%, with a confidence interval for the difference spanning zero. Renal-related adverse events were 4.0% versus 24.0% in the safety population.
Extension

Follow-up studies, subgroup analyses, and real-world validation

CREDIBLE-CR evaluated cefiderocol against best available therapy for serious carbapenem-resistant Gram-negative infections. Clinical and microbiological efficacy was similar in this heterogeneous population, but deaths by study end were numerically more frequent with cefiderocol (34% versus 18%), primarily among patients with Acinetobacter infections. RESTORE-IMI 1 studied imipenem/relebactam versus colistin plus imipenem for imipenem-nonsusceptible infections. Favorable overall response was 71% versus 70%; treatment-emergent nephrotoxicity was 10% versus 56% (P=.002). These results need to be interpreted within the studied pathogens, susceptibility criteria and populations.
Guidelines

Integration into clinical practice guidelines and recommendations

IDSA 2024 guidance addresses resistant Gram-negative infections in the United States and assumes the organism and susceptibility results are known.
Now

Current standard of care and ongoing research directions

Treatment decisions require identification of the causative organism and antibiotic susceptibility results. IDSA 2024 guidance provides preferred and alternative approaches for resistant Gram-negative infections in the United States, with suggested approaches applying to adults and children but doses provided only for adults. It recommends infectious diseases consultation and emphasizes that the field changes rapidly. Its evidence cutoff was December 31, 2023; later approvals or diagnostic and access claims require separate evidence.

Landmark Trials in This Story

The Lancet. Infectious diseases 2016Landmark

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study

Identification and characterization of MCR-1 resistance mechanism

The Lancet. Infectious diseasesSurveillance/epidemiological
TANGO II2018

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Clinical cure at end of treatment

Infectious diseases and therapyRandomized controlled trialN=77
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

Day-30 disposition

Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaComparative analysis of the prospective multicenter observational CRACKLE cohort
CREDIBLE-CR2021

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Clinical and microbiological outcomes at test of cure

The Lancet. Infectious diseasesRCTN=152
RESTORE-IMI 12020

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Favorable overall response

Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRandomized controlled trial

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How does colistin compare with newer treatments for CRE?+
CRACKLE associated ceftazidime–avibactam with lower adjusted 30-day hospital mortality than colistin for CRE infections (9% versus 32%), but it was observational. In RESTORE-IMI 1, treatment-emergent nephrotoxicity occurred in 10% with imipenem/relebactam versus 56% with colistin plus imipenem (P=0.002). These findings favor targeted alternatives in the studied settings without implying uniform effects across all resistant pathogens.
How do I choose between the new agents for CRE?+
The choice depends on the resistance mechanism.
What is cefiderocol and when should it be used?+
CREDIBLE-CR supports cefiderocol as an option for carbapenem-resistant infections when treatment options are limited, while highlighting numerically greater mortality, primarily in the Acinetobacter subset. It should not be described as universally effective across resistance mechanisms or as having the broadest beta-lactam spectrum.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026